Biotech Startup Pitch Deck: Build the 12 Slides Investors Need

What should a biotech startup pitch deck include?

A biotech startup pitch deck is an investor narrative that connects a defined patient or industrial problem to a specific asset, evidence package, development plan, and financing milestone. For a seed deck, Y Combinator recommends title, problem, solution, traction, metrics, insight, business model, market, team, and ask; keep each topic concise and avoid sets longer than three slides.

Biotech changes the emphasis. An early therapeutic company normally leads with target rationale, modality, preclinical evidence, translational plan, regulatory path, intellectual property, and the value-inflecting event the financing buys. The FDA describes five broad stages in drug development: discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring.

Use this 12-slide core deck

What is the best order for biotech pitch deck slides?

The strongest biotech pitch deck order moves from clinical or industrial urgency to biological plausibility, then to evidence, execution risk, and the capital request. Sequoia Capital’s company-plan framework similarly starts with a one-sentence purpose, then problem, solution, why now, market, competition, business model, team, financials, and the funding need.

Open with a sentence that makes the asset legible without jargon stacking: “We are developing [modality] against [target] for [defined population] to improve [measurable outcome].” The next slide should quantify the current burden with a primary source, then show why today’s standard fails. If you cannot state the endpoint and comparator, the problem is not ready for a funding deck.

Build the scientific middle in this order

• Mechanism slide: draw target → pathway → disease phenotype → endpoint; label what is established literature and what is your hypothesis.
• Evidence slide: use one study per panel; list model, n, controls, dose, time point, endpoint, absolute result, statistical method, and source.
• Differentiation slide: compare only like-for-like assets using target, modality, route, dosing, development stage, safety signal, biomarker strategy, and public clinical status.
• Development slide: show the next experiment or trial that can change company value, its pass or fail criterion, owner, dependency, and expected readout window.
• Capital slide: map each budget line to the development gate it buys; platform build is not a milestone unless it has an operational deliverable and decision consequence.

For clinical programs, distinguish discovery, preclinical, clinical research, review, and post-market activities rather than implying that preclinical efficacy is clinical validation. NCATS identifies early Phase 1, Phase 1, Phase 2, Phase 3, and Phase 4 as clinical-trial phases. Name the phase actually planned and its purpose instead of using clinical-stage loosely.

How do you show preclinical or clinical data in a biotech pitch deck?

Show biotech data as decision-grade evidence, not as a collage of favorable charts. The reader should identify the model, sample size, control, endpoint, time point, effect size, uncertainty, and study status in less than 30 seconds. Cite the publication, clinical-trial registry, regulatory document, or dated company dataset directly on the slide.

A preclinical evidence panel should name the biological model; disclose whether it is in vitro, ex vivo, animal, or computational; define the comparator; state n and biological versus technical replicates; and indicate whether the result is replicated. Do not turn a fold change into a therapeutic claim unless the endpoint is explicitly tied to the proposed indication.

Data-caption template to copy

For a clinical slide, lead with the protocol-defined primary endpoint, patient population, analysis set, and cut-off date. Put response rate, hazard ratio, biomarker change, adverse events, or pharmacokinetic exposure in the context specified by the protocol; never substitute an exploratory subgroup for the primary analysis without labeling it exploratory.

What can founders learn from biotech pitch deck examples?

Useful biotech pitch deck examples are models for information architecture, not proof that another company’s numbers, claims, or visual style fit your program. Pillar VC identifies problem, solution, market, competition, team, and use of proceeds as six essential biotech deck topics, and recommends showing roughly five top milestones alongside capital allocation.

Use public-company filings, clinical-trial registries, peer-reviewed papers, and regulatory documents as the factual layer for examples. They reveal what can be substantiated: a stated program stage, a named endpoint, an active trial, a disclosed risk factor, or an intended use of proceeds. Do not copy a competitor’s market estimate, projected timeline, or valuation logic without rebuilding it from current sources for your own indication and geography.

Three example patterns worth borrowing

• One asset, one sentence: state the target or platform output, modality, indication, and outcome before explaining the technical machinery.
• Evidence before aspiration: place the most decision-relevant figure before the platform architecture, then explain why the system produced that result.
• Capital tied to proof: define the round by the next value-inflecting package, such as candidate selection, IND submission, first patient dosed, or a protocol-specified readout.
• Comparable alternatives: show standard of care and direct competitors on matched dimensions, then state the unresolved risk your program is designed to reduce.
• Appendix discipline: prepare citations, assay protocols, extra cohorts, patent-support material, and sensitivity analyses for diligence rather than squeezing them onto the core slides.

A fair comparison avoids declaring that an asset is best based on one favorable attribute. Use a matrix with observable dimensions such as target, modality, route, dosing burden, patient segment, stage, biomarker, public efficacy evidence, public safety evidence, and IP position. Mark missing public information as not disclosed; do not infer superiority from absence of data.

How should a biotech startup pitch deck explain the funding ask?

A biotech funding ask should purchase a defined de-risking package, not merely time. State the round amount, current cash, monthly net burn, runway, spend by workstream, milestone date window, and the decision the data will enable. YC’s seed-deck guidance says that the ask should specify how much money is needed and what it gets the company, ideally placing it in a Series A-ready position within a year.

Calculate runway from actual cash and forecast net burn, then show the assumptions. Use a base case and one downside scenario tied to a genuine dependency such as CRO start-up, manufacturing slot availability, enrollment rate, or regulatory feedback. If an expected grant, partnering payment, or tax credit is not awarded or contracted, do not include it as committed runway.

Capital-to-milestone checklist

• Name the milestone: candidate nomination, GLP toxicology completion, IND clearance, first patient dosed, enrollment completion, or a protocol-defined readout.
• List workstreams: discovery, pharmacology, toxicology, CMC, clinical operations, regulatory, IP, and general and administrative.
• Assign each workstream a budget from current vendor quotes, signed statements of work, or documented internal plans; date every quote.
• Show the critical path and its dependencies, including assay qualification, manufacturing release, site activation, or agency interaction.
• State the pass or fail criterion and the financing consequence: advance, redesign, partner, pause, or prepare the next financing.

How can you make a biotech startup pitch deck with AnyGen?

Use AnyGen to convert a structured biotech evidence brief into an editable biotech startup pitch deck, then validate every scientific and financing claim before sharing it. The useful input is not a vague prompt: it is a slide-by-slide source sheet containing your indication, asset, target, modality, study results, development stage, cited comparables, budget, and milestone.

Start with 12 labeled inputs matching this page’s deck structure. For each data figure, provide the original chart or a table with model, n, controls, endpoint, values, statistical test, and source. For competition, provide a dated comparison table rather than a conclusion. For the financing slide, provide cash, forecast burn, vendor budget, milestones, dependencies, and the exact amount being raised.

Copy-and-do workflow

• Create a one-page scientific brief: asset, target, modality, indication, current stage, and next value-inflecting milestone.
• Create an evidence table for every slide: claim, supporting source, source date, confidence level, and owner who can verify it.
• Upload the brief, evidence tables, primary figures, and cited source links to AnyGen; request a 12-slide biotech startup pitch deck with an appendix for diligence material.
• Review each generated slide against the original evidence: check units, sample sizes, cohort labels, endpoints, dates, citations, and whether experimental versus clinical findings are clearly separated.
• Have the scientific founder, clinical or regulatory lead, and finance owner sign off on their respective slides before distribution.
• Export a clean meeting deck and retain the source-backed appendix for follow-up diligence.

AnyGen helps with deck construction, consistency, and editable visuals; it does not validate biology, predict regulatory outcomes, or replace scientific, clinical, legal, or financial review. Keep confidential study data and unpublished patent strategy inside your approved sharing workflow, and circulate only the version appropriate for the recipient.

Frequently asked questions